Render Target: STATIC
Render Timestamp: 2024-10-04T10:37:18.322Z
Commit: f04ddd7fea9fb3592f59f61482fcb94610d25cbe
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD20 (Rituximab Biosimilar) Human mAb #91213

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Human IgG1 kappa
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    CD20 (Rituximab Biosimilar) Human mAb is a biosimilar antibody for Rituximab. Rituximab is a therapeutic human monoclonal antibody directed against CD20 which is expressed on various B cell cancers such as some forms of B cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and B cell acute leukemia.
    Endotoxin <0.1 EU/μg of antibody

    Product Usage Information

    This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

    Formulation

    Supplied in 1X PBS, BSA and Azide Free.

    Storage

    Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

    Specificity / Sensitivity

    CD20 (Rituximab Biosimilar) Human mAb was confirmed to bind to its intended target protein CD20 using flow cytometry.

    Species Reactivity:

    Human

    Source / Purification

    CD20 (Rituximab Biosimilar) Human mAb is produced at Cell Signaling Technology. Rituximab is an antibody directed against the extracellular region of human CD20.

    Background

    B-lymphocyte antigen CD20 (also known as MS4A1; Membrane-spanning 4-domains subfamily A member 1) is a cell surface phosphoprotein involved in the regulation of B cell activation and proliferation (1,2). It is commonly used as a marker to identify B cells and is expressed throughout B cell development, up until their differentiation into plasma cells. CD20 has no known ligand, and its expression and function are largely conserved between human and mouse (1-3). Evidence suggests that CD20 is necessary for store operated calcium (SOC) entry, which leads to elevated cytoplasmic calcium levels required for B cell activation (4,5). Anti-CD20 antibody immunotherapy depletes B cells by activation of the innate monocytic network and is a common treatment for B cell lymphomas, leukemias, and autoimmune diseases (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.